# Vizgen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vizgen

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.vizgen.com
- Total disclosed funding: $292M
- Latest round: Series E (Dec 29, 2025)
- Investors on record: 8

## About

Vizgen, Inc. is a US-based company specializing in advanced spatial genomics solutions, particularly through its flagship product, the MERSCOPE Ultra™, which enhances single-cell analysis capabilities. Founded in 2019 in Cambridge, US, Vizgen, Inc. develops advanced spatial genomic technologies. The company was established by David Walt, Jeffrey Moffitt, Jiang He, and is currently led by CEO Peidong Wang. Vizgen specializes in advanced spatial genomics solutions, particularly through their flagship product, the MERSCOPE Ultra™. This high-plex, in situ single-cell spatial genomics platform integrates single-cell and spatial multiomics analysis powered by MERFISH technology. The MERSCOPE Ultra™ automates sample imaging, analysis, and cell segmentation, enabling high-resolution and high-throughput imaging without compromising sensitivity. The platform supports customizable panels that can analyze up to 1,000 genes, catering to a diverse range of research needs across various species and tissue types. Vizgen serves research institutions and academic laboratories engaged in neuroscience and cancer research across North America, Europe, and Asia, where there is a growing demand for advanced genomic analysis tools. Vizgen generates revenue primarily through the sale of the MERSCOPE Ultra™, along with associated reagents, consumables, and lab services. Transactions typically follow a B2B model, engaging directly with research institutions and laboratories through customized partnerships that often involve subscription-based arrangements for continued access to their technology and support services. Clients may purchase MERSCOPE 1000 Plex Gene Panels and the VPT Tool for Cell Segmentation as part of their research workflows. Pricing structures are aligned with the scale of usage and specific research needs, ensuring flexible options for various client requirements. The company plans to enhance its product offerings and expand into new markets, focusing on increasing its presence in Europe and Asia by mid-2025. The funding will also facilitate the development of new technologies and support ongoing operational initiatives. In January 2025, Vizgen, Inc. raised USD 48 million in venture funding led by returning investor ARCH Venture Partners, and co lead by Northpond Ventures and new investor M Ventures. The company will use the funding to fulfill its innovation strategy, broaden its global researcher support, and ramp up production capacity.

## Funding rounds

- Series E, Dec 29, 2025, $48M — ARCH Venture Partners, M Ventures, Northpond Ventures
- Series D, Oct 8, 2024, $108M — ARCH Venture Partners, Tao Capital Partners, Northpond Ventures
- Series C, Apr 21, 2022, $85M — ARCH Venture Partners, Sofina, Tao Capital Partners, Northpond Ventures, Blue Water Life Science Advisors, Novalis LifeSciences
- Series B, Mar 26, 2021, $37M — ARCH Venture Partners, Pura Vida Investments, Tao Capital Partners, Northpond Ventures, Novalis LifeSciences
- Series A, Oct 1, 2019, $14M — ARCH Venture Partners, Northpond Ventures

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B, Series C, Series D, Series E
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A, Series B, Series C, Series D, Series E
- Pura Vida Investments (https://capitalatlas.ai/funds/pura-vida-investments) — Series B
- Tao Capital Partners (https://capitalatlas.ai/funds/tao-capital-partners) — Series B, Series C, Series D
- Novalis LifeSciences (https://capitalatlas.ai/funds/novalis-lifesciences) — Series B, Series C
- Sofina — Series C
- Blue Water Life Science Advisors (https://capitalatlas.ai/funds/blue-water-life-science-advisors) — Series C
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series E